10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2020 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 25, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 7,082 | 9,777 | 6,193 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Amortization | 1,899 | 1,973 | 3,103 |
| Depreciation | 1,726 | 1,679 | 1,416 |
| Intangible asset impairment charges | 1,718 | 1,040 | 296 |
| Charge for the acquisition of VelosBio Inc. | 2,660 | 0 | 0 |
| Charge for the acquisition of Peloton Therapeutics, Inc. | 0 | 993 | 0 |
| Charge for future payments related to collaboration license options | 0 | 0 | 650 |
| Deferred income taxes | (668) | (556) | (509) |
| Share-based compensation | 475 | 417 | 348 |
| Other | (49) | 184 | 978 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (1,002) | 294 | (418) |
| Inventories | (855) | (508) | (911) |
| Trade accounts payable | 724 | 399 | 230 |
| Accrued and other current liabilities | (1,138) | 376 | (341) |
| Income taxes payable | 560 | (2,359) | 827 |
| Noncurrent liabilities | (453) | (237) | (266) |
| Other | (2,426) | (32) | (674) |
| Net Cash Provided by Operating Activities | 10,253 | 13,440 | 10,922 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (4,684) | (3,473) | (2,615) |
| Purchase of Seagen Inc. common stock | (1,000) | 0 | 0 |
| Purchases of securities and other investments | (95) | (3,202) | (7,994) |
| Proceeds from sales of securities and other investments | 2,812 | 8,622 | 15,252 |
| Acquisition of VelosBio Inc., net of cash acquired | (2,696) | 0 | 0 |
| Acquisition of ArQule, Inc., net of cash acquired | (2,545) | 0 | 0 |
| Acquisition of Antelliq Corporation, net of cash acquired | 0 | (3,620) | 0 |
| Acquisition of Peloton Therapeutics, Inc., net of cash acquired | 0 | (1,040) | 0 |
| Other acquisitions, net of cash acquired | (1,365) | (294) | (431) |
| Other | 130 | 378 | 102 |
| Net Cash (Used in) Provided by Investing Activities | (9,443) | (2,629) | 4,314 |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | 2,549 | (3,710) | 5,124 |
| Payments on debt | (1,957) | 0 | (4,287) |
| Proceeds from issuance of debt | 4,419 | 4,958 | 0 |
| Purchases of treasury stock | (1,281) | (4,780) | (9,091) |
| Dividends paid to stockholders | (6,215) | (5,695) | (5,172) |
| Proceeds from exercise of stock options | 89 | 361 | 591 |
| Other | (436) | 5 | (325) |
| Net Cash Used in Financing Activities | (2,832) | (8,861) | (13,160) |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | 253 | 17 | (205) |
| Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash | (1,769) | 1,967 | 1,871 |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6) | 9,934 | 7,967 | |
| Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6) | 8,165 | 9,934 | 7,967 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |